Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

BACKGROUND: The oral DPP-4 inhibitors are new incretin-based therapies for treatment of type 2 diabetes. To assess the efficacy and safety of three DPP-4 inhibitors (Saxagliptin, Sitagliptin and Vildagliptin) as add-on therapy to dual combination of traditional oral hypoglycemic agents in Chinese ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chun-Jun, Liu, Xiao-Juan, Bai, Lian, Yu, Qian, Zhang, Qiu-Mei, Yu, Pei, Yu, De-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050987/
https://www.ncbi.nlm.nih.gov/pubmed/24917890
http://dx.doi.org/10.1186/1758-5996-6-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050987/
https://www.ncbi.nlm.nih.gov/pubmed/24917890
http://dx.doi.org/10.1186/1758-5996-6-69

Ejemplares similares